Femasys To Participate in Upcoming BTIG Biotechnology Conference

Rhea-AI Summary

Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on women's health, will hold one-on-one virtual meetings during the BTIG Biotechnology Conference on August 8-9, 2022, at the St. Regis New York Hotel. The company develops minimally invasive technologies for reproductive health, including its lead products, FemBloc® for permanent birth control and FemaSeed® for infertility. Interested participants are encouraged to contact their BTIG representative for scheduling.

ATLANTA, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Company’s management team will be participating in one-on-one meetings virtually at the upcoming BTIG Biotechnology Conference. The conference, which will be held on a hybrid basis, is taking place at the St. Regis New York Hotel in in New York City on August 8-9, 2022.

If you are interested in meeting with Femasys at the conference, please reach out to your BTIG representative to schedule a meeting.

About Femasys
Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc^® permanent birth control and FemaSeed^® localized directional insemination for infertility. The Company’s product for fallopian tube assessment by ultrasound, FemVue^®, is currently marketed in the United States. Femasys is also advancing FemCath™, an intrauterine catheter for selective evaluation of the fallopian tubes and FemCerv^®, an endocervical tissue sampler that is the first product of the technology platform for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.

Contacts:

Investors
Chuck Padala
LifeSci Advisors, LLC
+1-917-741-7792
chuck@lifesciadvisors.com

Media
Karissa Cross, Ph.D.
LifeSci Communications
kcross@lifescicomms.com

Femasys Inc.
Investor Contact:
IR@femasys.com

Media Contact:
Media@femasys.com

FAQ

What is the BTIG Biotechnology Conference 2022?

The BTIG Biotechnology Conference 2022 is a hybrid event taking place on August 8-9 at the St. Regis New York Hotel, where companies like Femasys will engage in one-on-one meetings.

When will Femasys participate in the BTIG Biotechnology Conference?

Femasys will participate in one-on-one meetings during the BTIG Biotechnology Conference on August 8-9, 2022.

What products does Femasys focus on?

Femasys focuses on minimally invasive reproductive health technologies, including FemBloc® for permanent birth control and FemaSeed® for infertility.

How can I schedule a meeting with Femasys at the conference?

To schedule a meeting with Femasys at the conference, please contact your BTIG representative.

What are the lead product candidates of Femasys?

Femasys's lead product candidates include FemBloc® for permanent birth control and FemaSeed® for localized directional insemination.